Your Shopping Cart Is Empty
| Report Code: A02607 | Nov 2021 | Pages: 255 | ||
| Tables: 115 | Charts: 42 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Pulmonary Drug Delivery Systems Market
Request Now !Global pulmonary drug delivery systems market was valued at $49782.76 million in 2020, and is estimated to reach $ 91,128.61 million by 2030, growing at a CAGR of 6.08% from 2021 to 2030.
The COVID-19 outbreak is anticipated to have a positive impact on the growth of the global pulmonary drug delivery systems market as patients with asthma and COPD are considered at increased risk of dying from COVID-19. The COVID-19 pandemic has stressed the healthcare systems across the globe and has increased the need for the development of diagnostic instruments & treatment centers for people. A huge number of clinics, hospitals across the globe, were restructured to increase the hospital capacity for the patients diagnosed with COVID-19, this may also lead to the growth of the hospitalized inhalation drug delivery market in future. The rise in number of hospitals will increase the diagnosis of disease. Patient's response to respiratory symptoms may have been altered by the COVID-19 pandemic, making them less likely to seek care. This has significantly contributed toward the growth of the global market.
The term “targeted drug delivery” refers to directing the drug toward the targeted site. Pulmonary drug delivery is a type of targeted drug delivery system in which the drug moiety is directed toward the lower respiratory tract. The pulmonary drug delivery system refers to a device used to infuse drugs into the body through the pulmonary route. The inhalation route provides a better alternative for drug delivery for the treatment of asthma and chronic obstructive pulmonary disease. Pulmonary drug delivery provides immediate action which gives quick relief from asthmatic attacks and acute bronchitis. Aerosols are a particularly designed device, used for pulmonary drug delivery.
The global pulmonary drug delivery systems market is being driven primarily by an increase in air pollution, rise in prevalence of pulmonary diseases, such as asthma and chronic obstructive pulmonary disease; increase in number of hospitals & diagnostic centers; surge in funding from private & government organizations for treatment of pulmonary diseases and rise in awareness regarding pulmonary health. According to World Health Organization (WHO), 9 out of 10 people breathe air that contains high levels of pollutants and estimates show an alarming death toll of 7 million people every year caused by ambient (outdoor) and household air pollution in 2018
Furthermore, there is an increase in prevalence of chronic obstructive pulmonary diseases. It is a group of respiratory tract disease in which there is inflammation of lugs resulting in obstructive air flow. According to WHO, “Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death globally, which caused 3.23 million deaths in 2019.”
Moreover, development in pulmonary drug delivery systems is anticipated to contribute toward the growth of the market. For instance, in October 2018, Philips, a global leader in health technology, launched InnoSpire Go; a potable mesh nebulizer which is small in size ,light in weight, and easily portable hand-held nebulizer system designed to deliver drug in just four minutes. Furthermore, the rise in awareness among individuals for management & treatment of pulmonary diseases and rise in number of hospitals & diagnostic centers are expected to provide remunerative opportunities for the expansion of the global pulmonary drug delivery system market during the forecast period. Moreover, the presence of key manufacturing companies in pulmonary drug delivery system and advancement in the treatment for pulmonary diseases propel the growth of the market.
Thus, the presence of various healthcare foundations and government initiatives for the treatment of pulmonary diseases propel the growth of the market. However, high prices associated with pulmonary drug delivery system devices and inaccurate diagnosis of respiratory diseases restrict the market growth during the forecast period.
The global pulmonary drug delivery systems market is segmented into product, application, and distribution channel. On the basis of the product, the market is categorized into dry powder inhaler, metered dose inhaler, and nebulizers.
On the basis of application, it is divided into asthma, chronic obstructive pulmonary diseases, and cystic fibrosis. On the basis of distribution channel, it is categorized into retail pharmacies, hospital pharmacies, and e-commerce.
On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
On the basis of product, the metered dose inhaler segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to advancement in pulmonary drug delivery treatment, increase in number of hospitals & diagnostic centers, and surge in awareness regarding pulmonary healthcare. However, the dry powder inhalers segment is expected to grow significantly during the forecast period, owing to latest developments in pulmonary drug delivery devices.
By application, the asthma segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in air pollution leading to pulmonary diseases, and increase in number of hospitals and diagnostic centers. However, the Chronic Obstructive Pulmonary Disease (COPD) segment is expected to witness considerable growth during the forecast period, due to increase in diagnosis of pulmonary diseases and rise in smoking culture results in chronic bronchitis.
On the basis of distribution channel, the retail pharmacies segment dominated the market in 2020 and is expected to continue to dominate during the forecast period, owing to increase in retail pharmacies, rise in prevalence of pulmonary diseases, and development in R&D activities for lymphoma cancer treatment. However, the e-commerce segment is expected to witness considerable growth during the forecast period, owing to an increase in the number of internet users.
North America dominated the pulmonary drug delivery systems market in 2020 and is anticipated to remain dominant during the forecast period, owing to an increase in the prevalence of pulmonary diseases, presence of key players for manufacturing & developing drugs for pulmonary diseases, increase in number of hospitals & diagnostic centers and initiatives taken by government for pulmonary disease treatment in the region. However, Asia-Pacific is expected to register the highest CAGR of 7.1% from 2021 to 2030, owing to increase in prevalence of pulmonary diseases, rise in demand for pulmonary drug delivery, and presence of various healthcare foundations.
The key players operating in the global pulmonary drug delivery systems market include AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M Company, Actelion Pharmaceuticals Ltd (Janssen), Clement, Clarke International, Briggs Healthcare and Aerogen
Key Benefits For Stakeholders
Pulmonary Drug Delivery Systems Market Report Highlights
| Aspects | Details |
|---|---|
| By Product |
|
| By Application |
|
| By Distribution Channel |
|
| By Region |
|
| By Key Market Players |
|
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of pulmonary diseases
3.5.1.2.Increase in technological advancement in PDDS
3.5.1.3.Increase in Government policies and awareness programs by private organization
3.5.2.Restraint
3.5.2.1.High cost of pulmonary drug delivery system
3.5.3.Opportunity
3.5.3.1.Increase in research and development in pulmonary drug delivery system.
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the pulmonary drug delivery systems market
CHAPTER 4:PULMONARY DRUG DELIVERY SYSTEM, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Dry powder inhaler
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Dry powder inhaler, by type
4.2.2.1.Market size and forecast
4.2.2.2.Single Dose Inhaler
4.2.2.2.1.Market size and forecast
4.2.2.3.Multi Dose Inhaler
4.2.2.3.1.Market size and forecast
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Metered dose inhaler
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Metered dose inhaler, by type
4.3.3.1.Market size and forecast
4.3.3.2.Manually actuated pressurized inhaler
4.3.3.2.1.Market size and forecast
4.3.3.3.Breath actuated pressurized inhaler
4.3.3.3.1.Market size and forecast
4.3.4.Market analysis, by country
4.4.Nebulizer
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Nebulizer, by type
4.4.2.1.Market size and forecast
4.4.2.2.Jet nebulizer
4.4.2.2.1.Market size and forecast
4.4.2.3.Ultrasonic wave nebulizer
4.4.2.3.1.Market size and forecast
4.4.2.4.Vibrating mesh nebulizer
4.4.2.4.1.Market size and forecast
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
CHAPTER 5:PULMONARY DRUG DELIVERY SYSTEM, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Asthma
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Chronic obstructive pulmonary disease (COPD)
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Cystic fibrosis
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
CHAPTER 6:PULMONARY DRUG DELIVERY SYSTEM, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Retail pharmacies
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Hospital pharmacies
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.4.E-commerce
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
CHAPTER 7:PULMONARY DRUG DELIVERY SYSTEM MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America pulmonary drug delivery system market, by product
7.2.3.North America pulmonary drug delivery system market, by application
7.2.4.North America pulmonary drug delivery system market, by distribution channel
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. pulmonary drug delivery system market, by product
7.2.5.1.2.U.S. pulmonary drug delivery system market, by application
7.2.5.1.3.U.S. pulmonary drug delivery system market, by distribution channel
7.2.5.2.Canada
7.2.5.2.1.Canada pulmonary drug delivery system market, by product
7.2.5.2.2.Canada pulmonary drug delivery system market, by application
7.2.5.2.3.Canada pulmonary drug delivery system market, by distribution channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico pulmonary drug delivery system market, by product
7.2.5.3.2.Mexico pulmonary drug delivery system market, by application
7.2.5.3.3.Mexico pulmonary drug delivery system market, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe pulmonary drug delivery system market, by product
7.3.3.Europe pulmonary drug delivery systems market, by application
7.3.4.Europe pulmonary drug delivery systems market, by distribution channel
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany pulmonary drug delivery system market, by product
7.3.5.1.2.Germany pulmonary drug delivery system market, by application
7.3.5.1.3.Germany pulmonary drug delivery system market, by distribution channel
7.3.5.2.France
7.3.5.2.1.France pulmonary drug delivery system market, by product
7.3.5.2.2.France pulmonary drug delivery system market, by application
7.3.5.2.3.France pulmonary drug delivery system market, by distribution channel
7.3.5.3.UK
7.3.5.3.1.UK pulmonary drug delivery system market, by product
7.3.5.3.2.UK pulmonary drug delivery system market, by application
7.3.5.3.3.UK pulmonary drug delivery system market, by distribution channel
7.3.5.4.Italy
7.3.5.4.1.Italy pulmonary drug delivery system market, by product
7.3.5.4.2.Italy pulmonary drug delivery system market, by application
7.3.5.4.3.Italy pulmonary drug delivery system market, by distribution channel
7.3.5.5.Spain
7.3.5.5.1.Spain pulmonary drug delivery systems market, by product
7.3.5.5.2.Spain pulmonary drug delivery system market, by application
7.3.5.5.3.Spain pulmonary drug delivery system market, by distribution channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe pulmonary drug delivery system market, by product
7.3.5.6.2.Rest of Europe pulmonary drug delivery system market, by application
7.3.5.6.3.Rest of Europe pulmonary drug delivery system market , by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific pulmonary drug delivery system market, by product
7.4.3.Asia-Pacific pulmonary drug delivery system market, by application
7.4.4.Asia-Pacific pulmonary drug delivery system market, by distribution channel
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan pulmonary drug delivery system market, by product
7.4.5.1.2.Japan pulmonary drug delivery system market, by application
7.4.5.1.3.Japan pulmonary drug delivery system market, by distribution channel
7.4.5.2.China
7.4.5.2.1.China pulmonary drug delivery system market, by product
7.4.5.2.2.China pulmonary drug delivery system market, by application
7.4.5.2.3.China pulmonary drug delivery system market, by distribution channel
7.4.5.3.Australia
7.4.5.3.1.Australia pulmonary drug delivery system market, by product
7.4.5.3.2.Australia pulmonary drug delivery system market, by application
7.4.5.3.3.Australia pulmonary drug delivery system market, by distribution channel
7.4.5.4.India
7.4.5.4.1.India pulmonary drug delivery system market, by product
7.4.5.4.2.India pulmonary drug delivery system market, by application
7.4.5.4.3.India pulmonary drug delivery system market, by distribution channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea pulmonary drug delivery system market, by product
7.4.5.5.2.South Korea pulmonary drug delivery system market, by application
7.4.5.5.3.South Korea pulmonary drug delivery system market, by distribution channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific pulmonary drug delivery systems market, by product
7.4.5.6.2.Rest of Asia-Pacific pulmonary drug delivery system market, by application
7.4.5.6.3.Rest of Asia-Pacific pulmonary drug delivery system market, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA pulmonary drug delivery system market, by product
7.5.3.LAMEA pulmonary drug delivery system market, by application
7.5.4.LAMEA pulmonary drug delivery system market, by distribution channel
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil pulmonary drug delivery system market, by product
7.5.5.1.2.Brazil pulmonary drug delivery system market, by application
7.5.5.1.3.Brazil pulmonary drug delivery system market, by distribution channel
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia pulmonary drug delivery system market, by product
7.5.5.2.2.Saudi Arabia pulmonary drug delivery system market, by application
7.5.5.2.3.Saudi Arabia pulmonary drug delivery system market, by distribution channel
7.5.5.3.South Africa
7.5.5.3.1.South Africa pulmonary drug delivery system market, by product
7.5.5.3.2.South Africa pulmonary drug delivery system market, by application
7.5.5.3.3.South Africa pulmonary drug delivery system market, by distribution channel
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA pulmonary drug delivery systems market, by product
7.5.5.4.2.Rest of LAMEA pulmonary drug delivery system market, by application
7.5.5.4.3.Rest of LAMEA pulmonary drug delivery system market, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.3M company
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.Aerogen
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.3.AstraZeneca plc
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.Boehringer Ingelheim Gmbh
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.Briggs Healthcare
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product Portfolio
8.6.Clement Clarke International
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.7.GlaxoSmithKline plc
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.Janssen
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.Koninklijke Philips N.V. (Philips)
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Novartis AG
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY THERAPY, 2020–2030 ($MILLION)
TABLE 02.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 03.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR DRY POWDER INHALER, BY REGION, 2020–2030 ($MILLION)
TABLE 04.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR METERED DOSE INHALER, BY REGION, 2020–2030 ($MILLION)
TABLE 05.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 06.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 07.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR NEBULIZER, BY REGION, 2020–2030 ($MILLION)
TABLE 08.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 09.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR ASTHMA, BY REGION, 2020–2030 ($MILLION)
TABLE 10.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2020–2030 ($MILLION)
TABLE 11.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CYSTIC FIBROSIS, BY REGION, 2020–2030 ($MILLION)
TABLE 12.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 13.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR RETAIL PHARMACY, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 14.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 15.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR E-COMMERCE, BY REGION, 2020–2030 ($MILLION)
TABLE 16.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET , BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET WAS VALUED, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 22.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 23.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 24.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 26.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 27.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 28.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 29.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 30.EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 31.EUROPE PULMONARY DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 32.EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 33.EUROPE PULMONARY DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 35.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 36.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 37.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY PRODUCT, 2020-2030 ($MILLION)
TABLE 38.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 39.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 40.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 42.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 43.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 44.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 45.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 46.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 47.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 48.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 49.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY PRODUCT, 2020-2030 ($MILLION)
TABLE 50.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 52.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 53.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 57.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 58.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 59.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 60.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 61.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 62.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT 2020-2030 ($MILLION)
TABLE 63.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 65.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 66.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 67.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 68.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 69.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 74.LAMEA PULMNARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 75.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 76.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 77.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 79.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 80.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 81.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 82.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 84.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 85.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 87.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 88.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 90.3M: COMPANY SNAPSHOT
TABLE 91.3M: OPERATING SEGMENTS
TABLE 92.3M: PRODUCT PORTFOLIO
TABLE 93.AEROGEN: COMPANY SNAPSHOT
TABLE 94.AEROGEN: PRODUCT PORTFOLIO
TABLE 95.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 96.ASTRAZENECA SEGMENTS
TABLE 97.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 98.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 99.BOEHRINGER INGELHEIM SEGMENTS
TABLE 100.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 101.BRIGGS: COMPANY SNAPSHOT
TABLE 102.BRIGGS OPERATING SEGMENTS
TABLE 103.BRIGGS: PRODUCT PORTFOLIO
TABLE 104.CLEMENT CLARKE: COMPANY SNAPSHOT
TABLE 105.CLEMENT CLARKE: OPERATING SEGMENTS
TABLE 106.CLEMENT CLARKE: PRODUCT PORTFOLIO
TABLE 107.GSK: COMPANY SNAPSHOT
TABLE 108.GSK: OPERATING SEGMENTS
TABLE 109.GSK: PRODUCT PORTFOLIO
TABLE 110.JANSSEN: COMPANY SNAPSHOT
TABLE 111.JANSSEN: OPERATING SEGMENTS
TABLE 112.JANSSEN: PRODUCT PORTFOLIO
TABLE 113.PHILIPS: COMPANY SNAPSHOT
TABLE 114.PHILIPS: OPERATING SEGMENTS
TABLE 115.PHILIPS: PRODUCT PORTFOLIO
TABLE 116.NOVARTIS: COMPANY SNAPSHOT
TABLE 117.NOVARTIS: OPERATING SEGMENTS
TABLE 118.NOVARTIS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.PULMONARY DRUG DELIVERY SYSTEM MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTMES MARKET FOR DRY POWDER INHALER, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR METERED DOSE INHALER, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR NEBULIZER, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR ASTHMA, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CYSTIC FIBROSIS, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR E-COMMERCE, BY COUNTRY, 2020–2030 (%)
FIGURE 22.3M: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.3M: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24.3M: REVENUE SHARE BY REGION, 2020(%)
FIGURE 25.ASTRAZENECA: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.ASTRAZENECA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 28.BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.BOEHRINGER INGELHEIM: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2020(%)
FIGURE 31.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33.GSK REVENUE SHARE BY REGION, 2020(%)
FIGURE 34.JANSSEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.JANSSEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.JANSSEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.PHILIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 40.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE BY REGION, 2020(%)
The global pulmonary drug delivery system is a form of targeting in which the drug in the form of dispersed particles is inhaled with aerosol. Pulmonary drug delivery system provides immediate relief in the management of Asthma and COPD.
The factors such as rise in pollution and smoking habit in population, surge in approach for alternative drug delivery options, and increase in number of hospitals are expected to drive the growth of the pulmonary drug delivery system market. Moreover, the method for prophylaxis and treatment of COVID-19, further boost the growth of the market. However, improper diagnosis and formulation stability problems hamper the market growth.
North America is expected to experience the highest growth, in terms of revenue, owing to rise in the prevalence of pulmonary diseases, the presence of key players for manufacturing & developing drugs for pulmonary diseases, increase in number of hospitals & diagnostic centers, and initiatives taken by government for pulmonary disease treatment in the region.
Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to an increase in the prevalence of pulmonary disease, rise in the awareness regarding health, and presence of various healthcare foundations.
However, improper diagnosis of pulmonary disease and high price associated with pulmonary drug delivery devices are anticipated to restrain the market growth during the forecast period.
A. The total market value of pulmonary drug delivery systems market is $49782.76 million in 2020.
A. The forecast period in the report is from 2021 to 2030
A. The market value of pulmonary drug delivery systems Market in 2021 is $ 53,566.25 million
A. The base year for the report is 2020.
A. Yes, pulmonary drug delivery systems companies are profiled in the report
A. The top companies that hold the market share in pulmonary drug delivery systems market are AstraZeneca plc, Boehringer Ingelheim Gmbh, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M company, Janssen (Johnson & Johnson), Clement, Clarke International, Briggs Healthcare and Aerogen
A. Asia-Pacific is expected to register the highest CAGR of 7.1% from 2021 to 2030, owing to increase in prevalence of pulmonary diseases, technical advancements in pulmonary drug delivery systems, and government initiatives for treatment of pulmonary disease.
A. The key trends in thepulmonary drug delivery systems market are by an increase in the prevalence of pulmonary diseases, such as asthma, chronic pulmonary drug delivery systems, & cystic fibrosis, advancement in pulmonary drug delivery systems; government initiatives for treatment of pulmonary drug delivery systems.
Start reading instantly.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report